Clinical trials: Symptomatic Vitreomacular Adhesion
Vitreomacular Traction, Vitreomacular Adhesion
Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.
- Trial name
- NCT02322229
- Testing
- Ocriplasmin 0.125 mg in a 0.1 mL volume
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Alcon Research
Symptomatic Vitreomacular Adhesion
Ocriplasmin Research to Better Inform Treatment (ORBIT)
This is a multicenter, prospective, observational, Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by…
- Trial name
- ORBIT (NCT02079883)
- Where
- 110 sites in United States
- Volunteers
- 540 people
- Sponsor
- ThromboGenics
Vitreomacular Traction, Vitreomacular Adhesion
Assessment of Patients Treated With JETREA® for Vitreomacular Traction
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA®) over a 6-month follow-up period.
- Trial name
- NCT02035748
- Testing
- Ocriplasmin
- Volunteers
- 628 people
- Sponsor
- Alcon Research
Symptomatic Vitreomacular Adhesion
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
- Trial name
- NCT01889251
- Testing
- Ocriplasmin
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Alcon Research
Symptomatic Vitreomacular Adhesion
Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies
The primary objective of this study is to assess visual function in up to 44 patients who have previously participated in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007).
- Trial name
- NCT01287988
- Testing
- ocriplasmin
- Where
- 2 sites in United States, Belgium
- Volunteers
- 24 people
- Sponsor
- ThromboGenics
Symptomatic Vitreomacular Adhesion (VMA)
A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA
The purpose of this study is to retrospectively review and further characterize anatomic and symptomatic changes over six months immediately following treatment of symptomatic vitreomacular adhesion (VMA) with JETREA®…
- Trial name
- OZONE (NCT02193945)
- Where
- 24 sites in United States
- Volunteers
- 134 people
- Sponsor
- ThromboGenics
Symptomatic Focal Vitreomacular Adhesion
A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
Evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human subjects with symptomatic focal vitreomacular adhesion
- Trial name
- NCT02153476
- Testing
- 2.0mg of ALG-1001, Balanced Salt Solution
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Allegro Ophthalmics, LLC
Vitreomacular Adhesion Including Macular Hole
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.
- Trial name
- OASIS (NCT01429441)
- Testing
- Ocriplasmin
- Where
- 25 sites in United States
- Volunteers
- 220 people
- Sponsor
- ThromboGenics